Annovis Bio up on full enrollment in Alzheimer's drug trial

Annovis Bio

27/11/2023 15:37

** Shares of Annovis Bio  ANVS.N  up 12.6% to $7.3
    ** Drug developer reports its mid-to-late-stage trial
testing its lead experimental drug, buntanetap, in treating
Alzheimer's disease, exceeded full enrollment
    ** Since the initiation of the study in March, over 700
patients were screened and a total of 353 patients enrolled
across 54 sites in the United States - company
    ** Annovis is also testing the drug in a late-stage study as
a potential treatment for Parkinson's disease 
    ** YTD, stock down ~45% 

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))